Etomidate versus Ketamine as prehospital induction agent in patients with suspectedsevere traumatic brain injury.

Severe traumatic brain injury (TBI) is a leading cause of morbidity and mortality among young people around the world. Prehospital care focusses on the prevention and treatment of secondary brain injury and commonly includes tracheal intubation after induction of general anesthesia. The choice of induction agent in this setting is controversial. We therefore investigated the association between the chosen induction medication etomidate versus S(+)-ketamine , and the 30-day mortality in patients with severe TBI who received prehospital airway management in the Netherlands. We conducted a retrospective analysis of the prospectively collected observational data of the BRAIN-PROTECT cohort study. Patients with suspected severe TBI, who were transported to a participating trauma center and who received etomidate or S(+)-ketamine for prehospital induction of anesthesia for advanced airway management were included. Statistical analyses were performed with multivariable logistic regression and Inverse Probability of Treatment Weighting analysis. In total, 1457 patients were eligible for analysis. No significant association between the administered induction medication and 30-day mortality was observed in unadjusted analyses (etomidate 32.9% mortality versus S(+)-ketamine 33.8% mortality, p= 0.716, OR 1.04, 95% CI 0.83 to 1.32, p= 0.711) as well as after adjustment for potential confounders (OR 1.08, 95% CI 0.67 to 1.73, p= 0.765; risk difference 0.017, 95% CI -0.051 to 0.084, p= 0.686). Likewise, in planned subgroup analyses for patients with confirmed TBI and patients with isolated TBI, no significant differences were found. Consistent results were found after multiple imputation of missing data. We found no evidence for an association between the use of etomidate or S(+)-ketamine as an anesthetic agent for intubation in patients with TBI and mortality after 30 days in the prehospital setting, suggesting that the choice of induction agent may not influence patient mortality rate in this population.

Informations de copyright

Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Anesthesiologists.

Déclaration de conflit d'intérêts

Conflicts of Interest: SMB reported receiving grants from Achmea Healthcare Foundation during the conduct of the study. ARA reported receiving grants and personal fees from Becton Dickson and The Medicines Company; grants from Draeger; sponsor-initiated and funded phase 1 research from Rigel; and personal fees from PAION, Janssen Pharma, Ever Pharma, and Philips outside the submitted work. PS reported receiving grants from Dutch Brain Foundation and Achmea Healthcare Foundation during the conduct of the study. No other disclosures were reported.